Evidence map›Paper›PMID 40718488›Full record

ReviewFrontiers in immunology2025

From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors.

Mégane Jassin, Alix Block, Laury Désiront, Louise Vrancken, Céline Grégoire, Frédéric Baron, Grégory Ehx, Thi Tham Nguyen, Jo Caers

Erratum issuedAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Frontiers in immunology · 2026
    Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mégane JassinLaboratory of Hematology, Interdisciplinary Cluster for Applied Genoproteomics Institute (GIGA) Institute, University of Liege, Liege, Belgium.
Alix BlockLaboratory of Hematology, Interdisciplinary Cluster for Applied Genoproteomics Institute (GIGA) Institute, University of Liege, Liege, Belgium.
Laury DésirontLaboratory of Hematology, Interdisciplinary Cluster for Applied Genoproteomics Institute (GIGA) Institute, University of Liege, Liege, Belgium.
Louise VranckenLaboratory of Hematology, Interdisciplinary Cluster for Applied Genoproteomics Institute (GIGA) Institute, University of Liege, Liege, Belgium.
Céline GrégoireDepartment of Hematology, University Hospital of Liege, Liege, Belgium.
Frédéric BaronLaboratory of Hematology, Interdisciplinary Cluster for Applied Genoproteomics Institute (GIGA) Institute, University of Liege, Liege, Belgium.
Grégory EhxLaboratory of Hematology, Interdisciplinary Cluster for Applied Genoproteomics Institute (GIGA) Institute, University of Liege, Liege, Belgium.
Thi Tham NguyenLaboratory of Hematology, Interdisciplinary Cluster for Applied Genoproteomics Institute (GIGA) Institute, University of Liege, Liege, Belgium.
Jo CaersLaboratory of Hematology, Interdisciplinary Cluster for Applied Genoproteomics Institute (GIGA) Institute, University of Liege, Liege, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric Antigen Receptor T-cell (CAR-T) therapy is a revolutionary immunotherapy involving the genetic modification of T cells to express chimeric receptors targeting specific tumor antigens. Over the past decade, CAR-T therapy has significantly advanced with the development of five generations of CAR-T cells, each introducing modifications to enhance T cell efficacy, persistence, and the ability to overcome immune evasion mechanisms. The manufacturing of CAR-T cells has also evolved, employing techniques such as viral vector transduction or CRISPR-based gene editing, lipid nanoparticle, or transposon mediated approaches, to optimize their function. However, the development of CAR-T therapy for solid tumors faces significant challenges, primarily due to the hostile tumor microenvironment (TME), which traditional two-dimensional (2D) culture systems fail to accurately replicate. This review explores the potential of three-dimensional (3D) culture models, including spheroids and organoids, as tools for studying CAR-T cells in the context of solid tumors. Unlike 2D models, 3D systems offer a more physiologically relevant environment, better mimicking the TME, tumor heterogeneity, and immune interactions which CAR-T cells must encounter. We examine the advantages and limitations of 2D versus 3D models and discuss four key methods for generating spheroids/organoids: direct cell aggregation, scaffold-based, microfluidic, organs-on-chip and bioprinting, and patient-derived organotypic tumor approaches. Moreover, we explore the use of murine models in preclinical CAR-T research, highlighting their role in studying the dynamics of CAR-T cell trafficking, efficacy, and off-target effects. While CAR-T therapy has shown impressive success in some hematological malignancies, there is still a critical need for improved models to study CAR-T efficacy against solid tumors, particularly in relation to the TME. 2D models remain a valuable tool but should be combined with 3D models and

Indexed as

Immunotherapy, AdoptiveNeoplasmsOrganoidsReceptors, Chimeric AntigenSpheroids, CellularAnimalsCell Culture TechniquesCell Culture Techniques, Three DimensionalHumansTumor MicroenvironmentReceptors, Chimeric Antigen3D culturecar-tchimeric antigen receptor T cellsimmunotherapyorganoidsolid tumorspheroidtumor microenvironment

Identifiers

PMID40718488
PMCPMC12289599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.